A new clinical trial led by researchers in London, Canada has shown that high-dose radiation can improve survival in patients whose cancer had spread to 5 areas or less. The study looked at a technique called stereotactic ablative radiotherapy (SABR), which delivers a very high dose to a precise location. Patients who received the standard treatment of chemotherapy or radiation plus SABR lived 13 months longer than patients who received the standard treatment only. Five years after the treatment, twice as many patients who received SABR were alive compared to patients who got the standard therapy. Read more in an article from Global News.